Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
PRIMe-STAR
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
- NCT07150806 ↗
- Recruiting
- Joshua Palmer
- Focused
We haven't built an HCP commentary report on PRIMe-STAR (actinium ac 225 DOTATATE RYZ101 and L-lysine/L-arginine-containing amino acid in Recurrent Meningioma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PRIMe-STAR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Recurrent Meningioma
- Interventions
- Actinium Ac 225 DOTATATE RYZ101; Biospecimen Collection; Computed Tomography; Echocardiography Test; Gallium Ga 68-DOTATATE; L-lysine/L-arginine-containing Amino Acid; Magnetic Resonance Imaging; Multigated Acquisition Scan; Positron Emission Tomography; Somatostatin Receptor Positron Emission Tomography
- Arms
- Treatment (RYZ101) · Experimental
- Enrollment
- 30 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- Joshua Palmer with RayzeBio, Inc.
- Start
- Nov 12, 2025
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT07150806 · updated Aug 13, 2026